文献速递淋巴瘤

局限期弥漫性大B细胞淋巴瘤

Limited-stage diffuse large B-cell lymphoma.
PubMed 文献 · Blood · 2022-01-01

局限期弥漫性大B细胞淋巴瘤(LS-DLBCL)占所有DLBCL的25%至30%,10年总生存率至少70%至80%。本文综述了该病缺乏统一定义、PET扫描的应用、R-CHOP免疫化疗为基础的治疗、历史标准为3周期系统治疗联合受累部位放疗,以及近期研究聚焦于缩短免疫化疗和PET指导放疗的策略。

要点

  • LS-DLBCL占DLBCL的25%至30%,10年总生存率至少70%至80%。
  • LS-DLBCL尚无统一定义,一般指Ann Arbor I至II期且最大肿块直径<10 cm。
  • R-CHOP免疫化疗是治疗基础,历史标准为3周期系统治疗联合受累部位放疗。

核心结论

  • LS-DLBCL预后良好,10年总生存率至少70%至80%,但尚无统一定义,治疗策略正在演变。
  • 近期临床研究聚焦于通过缩短免疫化疗疗程和PET指导的放疗来最小化毒性并最大化疗效。

研究设计与样本

  • 本文为综合性综述,更新近期文献并为LS-DLBCL患者的临床实践整合提供建议。

主要发现

  • LS-DLBCL患者10年总生存率至少70%至80%。
  • LS-DLBCL一般定义为Ann Arbor I至II期且最大肿块直径<10 cm,但各研究间存在差异导致解读困难。
  • R-CHOP免疫化疗是LS-DLBCL的治疗基础,3周期系统治疗联合受累部位放疗是主要的历史标准。
  • 5年后持续复发风险及放疗的远期并发症对既往策略提出了挑战。
  • 更严格的基线分期和PET反应评估可能改善决策。

关键数值与推荐

  • LS-DLBCL一般定义为Ann Arbor I至II期且最大肿块直径<10 cm。
  • 历史标准联合模式治疗包括3周期系统治疗和受累部位放疗。

临床怎么用

  • R-CHOP免疫化疗是LS-DLBCL治疗的基础。
  • 更严格的基线分期和PET反应评估可能改善决策。
  • 近期研究探索缩短免疫化疗疗程和PET指导的放疗以最小化毒性并最大化疗效。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diffuse large B-cell lymphoma (DLBCL), the most common lymphoma subtype, is localized in 25% to 30% of patients. Prognosis in patients with limited-stage DLBCL (LS-DLBCL) is excellent with 10-year overall survival of at least 70% to 80%. Improved insights into the disease biology, the availability of positron-emission tomography (PET) scans, and recent dedicated clinical trials within this unique population have led to evolving treatment paradigms. However, no standard definition of LS-DLBCL exists, and although generally defined as Ann Arbor stages I to II disease with largest mass size <10 cm in diameter, variations across studies cause challenges in interpretation. Similar to advanced-stage disease, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) immunochemotherapy forms the basis of treatment, with combined modality therapy including 3 cycles of systemic treatment and involved-site radiation therapy being a predominant historical standard. Yet the well-described continuous risk of relapse beyond 5 years and established late complications of radiotherapy have challenged previous strategies. More rigorous baseline staging and response assessment with PET may improve decision making. Recent clinical studies have focused on minimizing toxicities while maximizing disease outcomes using strategies such as abbreviated immunochemotherapy alone and PET-adapted radiotherapy delivery. This comprehensive review provides an update of recent literature with recommendations for integration into clinical practice for LS-DLBCL patients.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Hawkes EA, Barraclough A, Sehn LH, et al. Limited-stage diffuse large B-cell lymphoma. Blood. 2022. PMID: 34932795. doi:10.1182/blood.2021013998

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。